Temozolomide and cisplatin combination in naive patients with metastatic cutaneous melanoma: results of a phase II multicenter trial.

@article{WierzbickaHainaut2010TemozolomideAC,
  title={Temozolomide and cisplatin combination in naive patients with metastatic cutaneous melanoma: results of a phase II multicenter trial.},
  author={Ewa Wierzbicka-Hainaut and Bruno Sassolas and Laurent Mourey and Bernard Guillot and Christophe B{\'e}dane and G{\'e}rard Guillet and Jean Marc Tourani},
  journal={Melanoma research},
  year={2010},
  volume={20 2},
  pages={141-6}
}
Temozolomide (TMZ) is a second-generation alkylating agent that has recently shown some efficacy in stage IV melanoma. The purpose of this study was to test the efficacy and safety of combination therapy with TMZ and cisplatin (CDDP) in patients with metastatic melanoma. Chemo-naive patients with metastatic cutaneous melanoma were included in a phase II study of combined therapy with TMZ (200 mg/m/day), days 1-5, and CDDP (75 mg/m/day) on day 1. The treatment was given every 28 days, for up to… CONTINUE READING
7 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-7 of 7 extracted citations

Similar Papers

Loading similar papers…